Drugs / IFNα-2a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04522557 | Aug 2020 → Jul 2021 | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07307586 Comparator | Sep 2025 → Dec 2026 expected | chronic hepatitis B virus infection | Zhigang Ren | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFN α-2a | “IFN α-2a treatment” NCT07307586 ↗ |
| Modality | Protein / enzyme biologic | “Interferons (IFNs) are pleiotropic cytokines” NCT04522557 ↗ |